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Abstract
Overweight and obesity are associated with increased high sensitivity C-reactive protein (hsCRP)
levels. The purpose of this study was to determine if weight loss diets differing in fat, protein, or
carbohydrate composition differentially reduce hsCRP. POUNDS (Preventing Overweight Using
Novel Dietary Strategies) LOST was a two-year trial of overweight and obese adults randomly
allocated to one of four weight loss diets with targeted percentages of energy derived from fat,
protein, and carbohydrates (20,15,65%;20,25,55%;40,15,45%;40,25,35%, respectively). hsCRP
was measured at baseline, 6, and 24 months among 710 participants, and adiposity as measured by
dual X-ray absorptiometry (N=340) or abdominal computed tomography (N=126) was correlated
with hsCRP change. At 6 months, hsCRP was reduced in all trial participants by −24.7% (IQR
+7%,−50%), weight by −6.7% (IQR −3%,−11%), and waist circumference by −6.0% (IQR −3%,
−10%) (all P<.002), with no significant differences according to dietary composition. The percent
change in hsCRP at 6 and 24 months correlated modestly with change in weight, waist
circumference, fasting insulin, fasting glucose, HOMA, and most lipid levels. Reductions in
hsCRP persisted despite an approximate 50% regain of weight by 24 months. The percent change
in hsCRP at 24 months significantly correlated with changes in total body fat (r=0.42), total
abdominal adiposity (r=0.52), subcutaneous abdominal adiposity (r=0.52), visceral adiposity
(r=0.47), and hepatic tissue density (r=−0.34) (all P<0.0006). In conclusion, weight loss decreased
hsCRP by similar magnitude, irrespective of dietary composition. Clinicians concerned about
inflammation and cardiovascular risk should recommend weight loss diets most likely to succeed
for their patients.
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Introduction
Overweight and obese individuals are more likely to have elevated levels of the
inflammatory biomarker high-sensitivity C-reactive protein (hsCRP),1 and both weight loss
and statin therapy are known to reduce hsCRP levels.2,3 Following publication of the
randomized placebo controlled JUPITER trial demonstrating the efficacy of statin therapy
for the primary prevention of cardiovascular events in patients with elevated levels of
hsCRP and normal levels of LDL cholesterol,2 some physicians have elected to prescribe
statin therapy for cardiovascular disease prevention for patients with isolated hsCRP
elevation. However, current recommendations suggest that lifestyle modification including
weight loss when appropriate should be first line therapy for primary prevention of
cardiovascular disease, even in patients with elevated LDL cholesterol.4 Despite popular
interest in “anti-inflammation diets,” few data have been presented describing whether diets
differing in fat, protein, or carbohydrate composition significantly modify the effect of
weight loss on hsCRP, and there are no clear guidelines about what kind of diet clinicians
should recommend to their patients with elevated hsCRP levels. Two small shortterm
randomized trials comparing weight loss diets differing in macronutrient composition
demonstrated that lower glycemic load diets preferentially decrease hsCRP despite similar
weight loss between groups.5,6 In contrast, one study (n=29) demonstrated an increase in
hsCRP on a low carbohydrate diet and a decrease in hsCRP on a high carbohydrate diet at
one month despite greater weight loss in the low carbohydrate group.7 Other small trials of
relatively short duration comparing weight loss diets differing in macronutrient composition
have shown no significant differences in hsCRP lowering.8–11 One short-term study
demonstrated a significantly greater reduction in hsCRP with higher fat Mediterranean-style
diets when compared to a low-fat diet despite minimal weight loss in all groups, suggesting
the importance of dietary factors independent of weight loss.12
In the recently completed NIH-funded POUNDS (Preventing Overweight Using Novel
Dietary Strategies) LOST trial, overweight individuals were randomly allocated over a 24
month period to one of four weight reduction diets differing in composition of fat, protein,
and carbohydrate. As previously reported, after 6 months of intervention, body weight was
significantly reduced to a similar degree in all four groups, and there was weight regain at 24
months for the majority of participants.13 Here we report data from the POUNDS LOST
trial addressing whether dietary composition impacts the reduction in hsCRP and whether
effects of weight loss on hsCRP that might be present at 6 months were sustained for the full
24 month trial period. Further, as a randomly selected subgroup of participants also
underwent dual X-ray absorptiometry (DXA) and computed tomography (CT), we also
tested whether changes in hsCRP with diet-induced weight loss were preferentially related
to changes in total body fat, abdominal fat, and/or hepatic fat.
Methods and Procedures
Participants and trial design
POUNDS LOST was a two-year randomized weight loss trial of 811 overweight and obese
(BMI 25–40 kg/m2) volunteers age 30–70, conducted between October 2004-December
2007 at two clinical research sites (Harvard School of Public Health and Brigham and
Women’s Hospital, Boston, Massachusetts; and Pennington Biomedical Research Center,
Baton Rouge, Louisiana).13 The human subjects committees at both sites approved the study
as did a data and safety monitoring board appointed by the National Heart, Lung, and Blood
Institute. All subjects gave informed consent in writing.
After the collection of baseline data, participants were randomized into one of four treatment
arms with targeted percentages of energy derived from fat, protein, and carbohydrates of 20,
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15, 65%; 20, 25, 55%; 40, 15, 45%; and 40, 25, 35%, respectively. The study design allowed
for a two-by-two factorial comparison of high fat vs. low-fat as well as high protein vs.
average protein diets, as well as a dose-response test of carbohydrate intake ranging from 35
to 65%. The dietary goals for all groups were similar: 8% or less of kilocalories from
saturated fat, 150 milligrams or fewer of cholesterol per 1000 kilocalories, and at least 20
grams of fiber daily. All diets adhered to healthy diet principles,14 and included suggestions
for low glycemic index carbohydrate-rich foods. Each participant received a tailored diet
prescription, based upon a 750 kilocalories/day energy deficit from total energy
requirements (as determined by resting energy expenditure measured via metabolic cart and
factoring in activity level), and rounded to the nearest 200 kilocalories. The physical activity
target was 90 minutes of moderate intensity exercise per week. An intensive behavioral
program accompanied all of the diet interventions.
Adherence to diet assignments was assessed in a random sample of 50% of participants
using 5-day diet records and 24 hour recalls, and was compared to biomarker data for
carbohydrate, protein, and fat intake. As reported in the main paper, there were greater mean
differences in macronutrient intake between the four diets at 6 months than has often been
seen in previous trials comparing diets of varying macronutrient composition in free-living
individuals, and the decreased adherence to macronutrient targets at 24 months is similar to
that seen in the few randomized weight loss studies with extended follow-up.15,16
Measurements
Anthropometry and body composition—Measurements of body weight and waist
circumference were conducted before breakfast on two different days at baseline, 6 months,
and 24 months. About 50% of enrolled participants in the POUNDS LOST trial were
randomly selected to receive DXA scans at baseline, 6 months, and 24 months, and about
50% of this subset (25% of participants) were randomly selected to undergo abdominal CT
scans at these timepoints.
Total and regional body composition were measured by DXA after an overnight fast using
the same QDR 4500A machine (Hologic Inc, Bedford, MA). We previously reported
reproducibility of mean (SEM) fat and lean tissue measurements in our laboratory of 1.09%
(0.15%) and 0.89% (0.28%), respectively.17 Fat mass was calculated from percent body fat
and body weight. CT measurements were performed by a GE High-Light Computed
Tomographic scanner (Milwaukee, WI) or GE LightSpeed–VCT (Milwaukee, WI). Eight
abdominal images were acquired to assess the area of visceral and subcutaneous adipose
tissue (Analyzetm; Lenexa, Kansas), and the sum of individual slices was used to calculate
total volume.18 Reader variability (coefficient of variation) averaged 0.9%. For correlations,
we excluded participants with incomplete abdominal data (N=26) due to abdominal girth not
fitting in the CT field. Hepatic density measured in Hounsfield units (HU) and corrected for
spleen density was used to assess hepatic fat infiltration. Given that prior work comparing
hepatic quantitative proton magnetic resonance spectroscopy with CT imaging indicates at
least 5% hepatic fat infiltration when liver minus spleen density is ≤6.29 HU, we conducted
an analysis restricted to participants with at least 5% baseline hepatic fat deposition to
examine the association between change in hepatic fat and change in hsCRP. For both CT
and DXA measurements, daily phantoms were used to ensure instrument stability over time,
and a 3-point body fat phantom was used to verify the accuracy of instruments across study
sites.
Biomarkers—Fasting blood samples were obtained at baseline, 6, and 24 months. The
procedures for measuring serum lipids, glucose, insulin, glycated hemoglobin (HbA1c), and
calculating the HOMA (homeostasis model assessment of insulin sensitivity) in POUNDS
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LOST have been detailed previously.13 For this analysis of hsCRP, we included 710
participants who provided a baseline blood sample and at least one follow-up blood sample,
provided baseline anthropometric data and anthropometric data at the blood sample
timepoints, and gave permission for their blood samples to be used for future studies. hsCRP
was measured using an immunoturbidimetric assay on the Hitachi 917 analyzer (Roche
Diagnostics, Indianapolis, IN) with reagents and calibrators from DiaSorin (Stillwater, MN).
The day-to-day variability of the assay at concentrations of 0.91, 3.07, and 13.38 mg/L are
2.81%, 1.61%, and 1.1%, respectively. To relate changes in body composition to changes in
hsCRP, we analyzed the data of participants who had been scanned at baseline and at least
one follow-up visit for DXA (n=340), abdominal CT (n=137), and CT measured liver
density (n=154).
Statistical Analysis
The primary outcome of this study was percent change in hsCRP at 6 and 24 months on
diets varying in composition of protein, fat, and carbohydrates. The change was evaluated
using ANOVAs, non-parametric Wilcoxon, and Wilcoxon signed rank tests using a two-
sided significance level of ≤0.05. Data were pooled for factorial comparisons of high vs. low
fat and high vs. average protein, and compared using Kruskal-Wallis tests for non-
parametric data. We used Spearman correlations to compare changes in hsCRP with changes
in weight loss, waist circumference, risk factors for cardiovascular disease and diabetes, and
changes in body composition. As a sensitivity analysis, we re-ran the correlations restricting
the analysis to only participants who had data for all three timepoints. All analyses were
performed using JMP 9 (SAS Institute Inc., 2011).
Results
Table 1 shows baseline characteristics of study participants. There were no significant
differences at baseline between treatment arms for demographic variables, baseline risk
factors, or hsCRP levels. Table 2 presents data stratified by diet assignment on weight, waist
circumference, and hsCRP at baseline, 6, and 24 months. For the total study population,
hsCRP declined by 24.7% at 6 months (P<.0001), an effect that was largely maintained at 24
months (−22.9%, P<.0001 for change from baseline). Consistent with previous reports for
the entire cohort,13 weight was reduced by 6.7% at 6 months (P<.0001) and 3.9% at 24
months (P<.0001 for change from baseline), and waist circumference was reduced by 6.0%
at 6 months (P<.0001) and 4.7% at 24 months (P<.0001 for change from baseline).
As shown in Table 2, reductions in hsCRP over time were of similar magnitude across all
dietary composition groups. Specifically, hsCRP levels were reduced at 6 months by 29.9%,
23.4%, 24.8%, and 23.5%, among those in the low-fat/average protein, low-fat/high protein,
high-fat/average protein, and high-fat/high protein groups, respectively (P between
groups=0.76). Similarly, hsCRP was reduced at 6 months by 25.3% and 23.7% in the low-
fat and high-fat groups, respectively (P=0.83), and by 27.7% and 23.5% in the average
protein and high protein groups, respectively (P=0.41). There was no significant difference
(P=0.50) between the change in hsCRP at 6 months for the lowest (−23.5%) and highest
carbohydrate groups (−29.9%). Effects on hsCRP persisted at 24 months in all groups,
despite regain of weight and waist circumference.
As reductions in hsCRP were not significantly different according to randomized dietary
interventions, we combined the study sample for subsequent analyses seeking to understand
correlates of hsCRP change. Table 3 shows baseline hsCRP as well as changes in hsCRP
and weight over time in various subgroups. We noted significant differences in hsCRP at
baseline between men and women, Caucasians and African-Americans, overweight and
obese participants, participants using lipid lowering therapy vs. those who were not, and
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postmenopausal women using hormones vs. those who were not. Despite these significant
differences at baseline, there was no difference in hsCRP lowering at 6 and 24 months
except for postmenopausal women using hormones. Compared to women not on hormone
therapy, postmenopausal women on hormone therapy had a significantly greater reduction in
hsCRP at 24 months (P=0.0139).
Figure 1 presents the change in anthropometric measurements, lipid-related risk factors,
metabolic risk factors, and hsCRP for the entire study population. There were minimal
changes in fasting blood glucose and HbA1c over the course of the study, and total
cholesterol, LDL, and HDL changed by less than 10%. In contrast, the 20% reduction in
triglycerides, fasting insulin, and HOMA was similar to the change in hsCRP. These effects
persisted for triglycerides and hsCRP at 24 months but were largely attenuated for fasting
insulin and HOMA. Spearman correlation coefficients relating the percent change in hsCRP
and the change in weight, waist circumference, lipids, and metabolic variables are presented
in Table 4. The strongest correlations with change in hsCRP were with percent change in
weight (r=0.48), waist circumference (r=0.42), insulin (r=0.32), and HOMA (r=0.32).
Smaller but statistically significant correlations were also observed for percent change in
lipid levels and HbA1c, particularly at the end of 24 months of follow-up. These correlations
were not substantially altered when the analysis was restricted to participants with data at all
three timepoints.
Among participants who underwent DXA scanning (n=340), median fat loss was 4.7 kg
(−2.6%) and 3.1 kg (−1.6%) at 6 and 24 months (P<.0001 for both timepoints), respectively.
For participants who underwent abdominal CT scanning, median total abdominal fat loss
was −2.9 kg at 6 months and −2.1 kg at 24 months. The loss of visceral abdominal fat tissue
was −0.9 kg at 6 months and −0.7 kg at 24 months, while abdominal subcutaneous fat losses
were −1.9 kg at 6 months and −1.3 kg at 24 months (P<.0001 for change at all timepoints).
At 6 and 24 months there was a significant (P<.0001) increase in hepatic density (signifying
a decrease in fatty infiltration) of +2.4 HU (IQR 0.2, 6.2) and +3.6 HU (IQR −0.5, +7.7),
respectively. Table 4 shows that the percent change in hsCRP correlated significantly with
changes in total body fat, total abdominal adiposity, subcutaneous abdominal adiposity,
visceral adiposity, and hepatic tissue density (all P<.0006). In the participants with at least
5% hepatic fat infiltration present at baseline (53/154, 34%), the correlations between
percent change in hsCRP and change in hepatic fat were magnified, (6 months: r=−0.36,
P=0.0076; 24 months r=−0.47, P=0.0030).
Discussion
In this randomized trial of four weight reduction diets, we observed the association between
weight loss and substantial reductions in hsCRP, an effect that was independent of
macronutrient composition. Further, among those randomized to imaging studies, we
observed that the percent reduction in hsCRP correlated similarly with changes in all
measures of body fat including total fat, abdominal fat, and intrahepatic fat.
Our data confirm prior work from smaller studies demonstrating that diet-induced weight
loss substantially reduces hsCRP.3,19,20 In a systematic review of 28 lifestyle weight loss
studies ranging from 14 to 90 participants, the weighted correlation between change in
hsCRP and change in weight was 0.30,3 similar to our 6 month correlation coefficient of
0.31. The decrease in hsCRP with weight loss in our study is also similar to that observed
among participants with impaired glucose tolerance in the Diabetes Prevention Program
(DPP), where a 6.7% reduction in body mass was associated with a 30% reduction in
hsCRP,21 and among participants with diabetes participating in the Look AHEAD trial,
where 8.8% weight loss at one year was associated with a 44% decrease in hsCRP.22
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Similarly, studies of bariatric surgery show substantial reductions in hsCRP with weight
loss.23,24 Thus, our current data from POUNDS LOST in conjunction with other randomized
evidence demonstrate that weight reduction decreases hsCRP by amounts similar to that
reported with statin therapy.
Despite evidence for the effect of weight loss on hsCRP, there are scant prior data about the
optimal content of weight loss diets that should be prescribed to decrease inflammation, and
studies demonstrate conflicting results.5–11 In our large randomized trial, the macronutrient
composition of four different weight loss diets did not affect the change in hsCRP at 6 or 24
months. Similarly, there was no difference between high and average protein diets, between
high and low fat diets, or when the highest carbohydrate diet was compared to the lowest
carbohydrate diet. These findings suggest that macronutrient composition is unlikely to have
a differential effect on the reduction of hsCRP with weight loss.
In our trial, there was no difference in the percent change in hsCRP at 6 and 24 months
between African-Americans and Caucasians despite significant differences in percent weight
loss over time. Similarly, the percent reduction in hsCRP did not differ between overweight
and obese individuals or by gender. As anticipated, participants using lipid lowering therapy
at baseline had significantly lower baseline hsCRP values. However, as also observed in the
LOOK AHEAD trial,22 statin users had similar reductions in hsCRP with weight loss as
non-statin users. Taken together, these findings suggest that weight loss will further decrease
hsCRP in patients who are already experiencing a reduction in hsCRP from taking statins.
Consistent with other studies examining anthropometric, cardiovascular, and metabolic
correlates of hsCRP, we found the largest correlation coefficients for change in weight and
waist circumference.21 In addition, several cross-sectional analyses suggest that high hsCRP
levels are related to measures of insulin resistance, including fasting insulin and HOMA-
IR.25,26 In our study, changes in HOMA and insulin were more correlated with changes in
hsCRP than changes in LDL, especially at 24 months. This may be because of the relatively
greater impact of weight loss and a healthy diet on hsCRP and insulin levels than upon LDL.
While some cross-sectional studies suggest that visceral fat is more highly correlated with
hsCRP than abdominal subcutaneous fat,27,28 other cross-sectional studies suggest that
hsCRP is correlated similarly with abdominal subcutaneous fat and visceral fat.29,30
However, few studies have examined how changes in these fat depots with weight loss relate
to changes in hsCRP over time.31 In our randomized trial, the percent change in hsCRP
correlated similarly with changes in all measures of body fat, including total body fat, and
total abdominal, subcutaneous abdominal, and visceral fat. This similar effect is likely
because of the similar fat reduction in all compartments in this study.
Hepatic steatosis is associated with both cardiovascular disease risk32 and elevated
hsCRP.33 Previous studies demonstrate that hepatic fat infiltration can be reversed with
weight loss,34 but few studies have examined how changes in hepatic steatosis with weight
loss relate to changes in hsCRP.35 In our study we note a reversal of fat infiltration with
weight loss which is significantly correlated with the change in hsCRP over time, a
correlation which was magnified in those individuals who had significant hepatic steatosis at
baseline.
In this trial, hsCRP levels did not rebound, despite significant weight re-gain by 24 months,
an observation seen previously in other studies.21,22 Similarly, in one six month weight
maintenance study of 932 adults, hsCRP levels continued to decrease despite slight weight
regain, although this effect was more pronounced in the low glycemic index maintenance
diets.36 The persistent changes in hsCRP noted in our study may reflect remodeling at the
level of adipose tissue, including changes in adipocyte size and/or gene expression,37,38 that
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could be contributing to a decrease in hsCRP production. Given that all participants were
placed on healthy diets that adhere to current recommendations, including fiber intake,
carbohydrate quality, and type of fat, it is also possible that participants continued a
healthier diet overall despite weight re-gain, regardless of their diet assignment. This is
consistent with some studies demonstrating the importance of diet quality, particularly the
Mediterranean diet, for reducing inflammation, possibly by modifying inflammatory
pathways.19,39 Alternatively, it may be that a particular threshold of weight loss needs to be
maintained. Further studies should examine the mechanisms responsible for this effect.
Strengths of our trial include the large diverse population as well as a larger proportion of
men (39%), lower drop out rate (20%), and longer follow-up (2 years) than most weight loss
studies. The addition of imaging measures of body fat allowed us to examine how changes
in body composition relate to changes in hsCRP. Nonetheless, limitations of our analysis
merit consideration. Not all of our participants had data at all three timepoints. However, a
sensitivity analysis conducted among subjects with complete data demonstrated that the
correlations were not substantially different. In addition, since all participants were advised
to choose carbohydrate-rich foods with a low glycemic index, the study does not allow for a
true comparison between low and high glycemic index diets. However, the fact that there
were no significant differences in hsCRP between those assigned to 35% and 65%
carbohydrate diets suggests that total carbohydrate content does not significantly affect
hsCRP. Finally, as all groups in POUNDS LOST had similar exercise recommendations, we
cannot evaluate the effect of physical activity separately from weight loss. However, the
recent INFLAME study found that exercise training without weight loss is not associated
with a reduction in hsCRP.40
In conclusion, our analysis indicates that diet induced weight loss results in a substantial
reduction of hsCRP that is of similar magnitude to statin therapy and is independent of
macronutrient composition. As such, physicians concerned about elevated hsCRP levels in
their patients should emphasize the importance of weight loss, and suggest that patients
choose a weight loss diet that would be most likely to lead to success, regardless of
macronutrient composition.
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Figure 1.
The median percent change from baseline at 6 months (light gray bars) and 24 months (dark
gray bars) among all participants for weight, BMI, waist circumference, total cholesterol,
low-density lipoprotein, high-density lipoprotein, triglycerides, fasting glucose, fasting
insulin, HOMA, HbA1c, and hsCRP. The dot represents the medians, and the bars show the
range from the 25th to the 75th percentile.
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Table 3
Change from baseline in hsCRP and body weight at 6 and 24 months by subgroup among participants (n=710)
Characteristic Baseline
CRP
median
(IQR)
P value
between
groups at
baseline
6m median
hsCRP
change
from
baseline in
mg/L
(median %
change)
P value
between
groups
for %
hsCRP
change
6m median
change from
baseline in
wt
in kg
(median
% change)
P value
between
groups
for %
wt
change
24 median
hsCRP
change
from
baseline in
mg/L
(median %
change)
P value
between
groups
for %
hsCRP
change
24m median
change from
baseline in
wt
in kg
(median
% change)
P value
between
groups
for %
wt
change
Gender:
  Female (n=435) 2.2 (1.1,4.3) −0.4 (−24%) −5.8 (−6.5%) −0.3 (−20%) −2.8 (−3.2%)
  Male (n=275) 1.6 (0.8,2.7) <.0001 −0.4 (−27%) 0.31 −6.8 (−6.8%) 0.81 −0.3 (−28%) 0.08 −3.9 (−3.7%) 0.28
Race:
  Caucasian (n=579) 1.8 (0.9,3.4) −0.4 (−25%) −6.6 (−7.2%) −0.3 (−24%) −3.7 (−4.1%)
  Black (n=100) 2.4 (1.2,4.8) 0.0032 −0.5 (−24%) 0.65 −3.9 (−4.2%) <.0001 −0.4 (−21%) 0.70 −1.0 (−1.1%) .0011
Age:
  ≤50 years old (n=295) 1.8 (0.8,3.6) −0.4 (−23%) −5.6 (−6.0%) −0.2 (−23%) −2.8 (−3.0%)
  >50 years old (n=415) 1.9 (0.9,3.5) 0.64 −0.4 (−28%) 0.34 −6.5 (−7.2%) 0.0149 −0.4 (−23%) 0.32 −3.5 (−4.0%) .0362
BMI:
  <30 (n=180) 1.2 (0.6,2.4) −0.2 (−24%) −6.0 (−7.3%) −0.2 (−21%) −2.8 (−3.6%)
  ≥30 (n=493) 2.2 (1.1,4.1) <.0001 −0.5 (−25%) 0.34 −6.4 (−6.5%) 0.72 −0.4 (−23%) 0.21 −3.5 (−3.5%) 0.67
Lipid lowering medicine:
  Yes (n=135) 1.4 (0.7,2.6) −0.3 (−32%) −6.6 (−6.8%) −0.2 (−22%) −4.0 (−4.3%)
  No (n=575) 2.0 (0.9,3.8) 0.0019 −0.4 (−24%) 0.38 −6.1 (−6.7%) 0.48 −0.4 (−22%) 0.87 −2.9 (−3.3%) 0.26
Use of hormones among
post-menopausal
women:
  Yes (n=80) 2.9 (1.5,4.7) −0.8 (−26%) −7.0 (−8.6%) −0.6 (−37%) −2.1 (−2.2%)
  No (n=161) 1.8 (1.0,3.4) 0.0029 −0.4 (−24%) 0.64 −5.7 (−6.4%) 0.17 −0.3 (−19%) 0.0139 −3.7 (−4.7%) 0.55
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Table 4
Spearman correlation coefficients for the percent change in hsCRP and the percent change in weight, waist
circumference, lipids, metabolic factors, percent change in total body fat, and absolute change in total
abdominal fat, visceral fat, subcutaneous abdominal fat, and hepatic fat at 6 and 24 months
Measurement Percent change in
hsCRP at 6 months
Percent change in
hsCRP at 24 months
Percent change in body weight 0.31* 0.48*
(n=675) (n=568)
Percent change in waist circumference 0.25* 0.42*
(n=675) (n=568)
Percent change in total cholesterol 0.11* 0.10*
(n=675) (n=568)
Percent change in LDL 0.08* 0.10*
(n=675) (n=568)
Percent change in HDL −0.01
−0.21*
(n=675) (n=568)
Percent change in triglycerides 0.08* 0.20*
(n=675) (n=568)
Percent change in fasting glucose 0.11* 0.19*
(n=675) (n=568)
Percent change in fasting insulin 0.15* 0.32*
(n=675) (n=568)
Percent change in HOMA 0.16* 0.32*
(n=675) (n=568)
Percent change in HbA1c 0.03 0.15*
(n=675) (n=568)
Percent change in total body fat (DXA) 0.25* 0.42*
(n=330) (n=235)
Change in total abdominal adipose 0.36* 0.52*
tissue (CT) (n=117) (n=89)
Change in visceral abdominal adipose 0.33* 0.47*
tissue (CT) (n=117) (n=89)
Change in subcutaneous abdominal 0.35* 0.52*
adipose tissue (CT) (n=117) (n=89)
Change in hepatic density (CT)
−0.30* −0.34*
(n=147) (n=112)
*Significant at p<.05
Obesity (Silver Spring). Author manuscript; available in PMC 2013 October 01.
